Is the Canon Mab a Non-Existing Drug?

Adjouhaum also casts along shadow in terms of the payment environment because CMS, Medicare came out with this coverage decision where essentially they're not going to cover amyloid lowering drugs. So if the Canon Mab wins accelerated approval this week, that really just sets in motion the process by which ASI has to make its case more broadly. Around 85 to 90% of people who would meet the criteria for this drug that early stage of Alzheimer's disease are Medicare beneficiaries.